Although recent FDA approvals on ipilimumab and sipuleucel-T represent major milestones, the ultimate success of immunotherapy approaches will likely benefit from appropriate combinations with other immunotherapeutic and/or non-immunotherapeutic approaches. However, implementation of ideal combinations in the clinic may still face formidable challenges in regulatory, drug-availability and intellectual property aspects. The 2011 SITC annual meeting hosted a workshop on combination immunotherapy to discuss: 1) the most promising combinations found in the laboratory; 2) early success of combination immunotherapy in clinical trials; 3) industry perspectives on combination approaches, and 4) relevant regulatory issues.Authors: Ivan Martinez Forero, Hideho Okada, Suzanne L. Topalian, Thomas F. Gajewski, Alan J. Korman and Ignacio MeleroPublished as a meeting report in the Journal of Translational Medicine (2012) 10:108.#SITCPublication